|
|
James B. Dale, Edna Y. Chiang, Shaoyou Liu, Harry S. Courtney, David L. Hasty
J Clin Invest. 1999;
103(9):1261
doi:10.1172/JCI5118
Abstract |
Full text
| PDF

I
t is widely believed that the surface M protein of group A streptococci is the predominant surface protein of these organisms containing opsonic epitopes. In the present study, we identified a new surface protein, distinct from M protein, that evokes protective antibodies. A type 18 M-negative mutant was found to be both resistant to phagocytosis in human blood and virulent in mice. The wild-type strain, but not the M-negative mutant, was opsonized by antisera against purified recombinant M18 protein or a synthetic peptide copying the NH2-terminus of M18. However, antisera raised against a crude pepsin extract of the M-negative mutant opsonized both strains, indicating the presence of a protective antigen in addition to type 18 M protein. This antiserum was used to identify and purify a 24-kDa protein fragment (Spa, streptococcal protective antigen) that evoked antibodies that opsonized the M18 parent and the M-negative mutant. The results of passive mouse protection tests confirmed the presence of protective epitopes within Spa. The deduced amino acid sequence of a 636-bp 5′ fragment of the spa18 gene showed no homology with sequences in GenBank. These studies reveal the presence of a new protective antigen of certain strains of group A streptococci that may prove to be an important component of vaccines to prevent streptococcal infections.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(20)
| Title and authors |
Publication |
Year |
New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci
James B. Dale, Thomas A. Penfound, Edna Y. Chiang, William J. Walton
|
Vaccine
|
2011 |
Vaccines under study: non-HIV vaccines
Kelly Conner, Alice Wuu, Victoria Maldonado, Brenda L. Bartlett, Stephen K. Tyring
|
Dermatologic Therapy
|
2009 |
Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci
E. A. Ahmed, T. A. Penfound, S. C. Brewer, P. A. Tennant, E. Y. Chiang, J. B. Dale
|
Eur J Clin Microbiol Infect Dis
|
2009 |
Localization of the equine IgG-binding domain in the fibrinogen-binding protein (FgBP) of Streptococcus equi subsp. equi
M. Meehan, M. J. Lewis, C. Byrne, D. O'Hare, J. M. Woof, P. Owen
|
Microbiology
|
2009 |
Human pathogenic streptococcal proteomics and vaccine development
Jason N. Cole, Anna Henningham, Christine M. Gillen, Vidiya Ramachandran, Mark J. Walker
|
Prot. Clin. Appl.
|
2008 |
Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein
Harry S. Courtney, David L. Hasty, James B. Dale
|
Mol Microbiol
|
2006 |
Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome
Manuel J RodrÃguez-Ortega, Nathalie Norais, Giuliano Bensi, Sabrina Liberatori, Sabrina Capo, Marirosa Mora, Maria Scarselli, Francesco Doro, Germano Ferrari, Ignazio Garaguso, Tiziana Maggi, Anita Neumann, Alessia Covre, John L Telford, Guido Grandi
|
Nat Biotechnol
|
2006 |
Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development
Jason D. McArthur, Mark J. Walker
|
Mol Microbiol
|
2006 |
A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults
Shelly A. McNeil, Scott A. Halperin, Joanne M. Langley, Bruce Smith, Darlene M. Baxendale, Andrew Warren, Geoffrey P. Sharratt, Mark A. Reddish, Louis F. Fries, Peter E. Vink, James B. Dale
|
International Congress Series
|
2006 |
Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers
S. A. McNeil, S. A. Halperin, J. M. Langley, B. Smith, A. Warren, G. P. Sharratt, D. M. Baxendale, M. A. Reddish, M. C. Hu, S. D. Stroop, J. Linden, L. F. Fries, P. E. Vink, J. B. Dale
|
CLIN INFECT DIS
|
2005 |
|